Literature DB >> 15740512

Non-sentinel lymph node metastases in breast cancer patients with metastatic sentinel nodes.

Wai-Ka Hung1, Miranda Chi-Mui Chan, Kong-Ling Mak, Sui-Fan Chong, Yvonne Lau, Chiu-Ming Ho, Andrew Wai-Chun Yip.   

Abstract

BACKGROUND: Sentinel lymph node biopsy (SLNB) has been shown to be relatively accurate in axillary nodal staging in breast cancer. In more than half of the patients with metastatic sentinel lymph node (SLN), the SLN was the only lymph node involved in the axilla.
METHODS: A retrospective analysis was performed for those female Chinese breast cancer patients who underwent SLNB. All patients had axillary dissection after SLNB. Those patients with metastatic SLN were selected for analysis. Various tumour factors and SLN factors were analysed to study the association with residual lymph node metastasis.
RESULTS: A total of 139 SLNB was performed. The success rate of SLN localization, false negative rate and accuracy were 92%, 9% and 95%, respectively. Fifty-five patients had metastases in the SLN. In 38 patients (69%), SLN was the only lymph node involved in the axilla. Tumours <3 cm, a single metastatic SLN, presence of micro metastases and the absence of extracapsular spread in the SLN were associated with the absence of metastasis in the non-sentinel lymph nodes.
CONCLUSION: Sentinel lymph node biopsy is accurate in the nodal staging of Chinese breast cancer patients. Several factors such as tumour <3 cm, a single metastatic SLN, micro metastases and the absence of extracapsular spread in the sentinel node(s) are useful predictors for the absence of residual disease in the axilla. With further studies and verification, these factors may prove to be important in determining which patients with metastatic SLN will require further axillary treatment. Until such information is available, axillary dissection should be performed when positive sentinel nodes are found.

Entities:  

Mesh:

Year:  2005        PMID: 15740512     DOI: 10.1111/j.1445-2197.2005.03283.x

Source DB:  PubMed          Journal:  ANZ J Surg        ISSN: 1445-1433            Impact factor:   1.872


  6 in total

1.  Implication of extracapsular invasion of sentinel lymph nodes in breast cancer: prediction of nonsentinel lymph node metastasis.

Authors:  Takaaki Fujii; Yasuhiro Yanagita; Tomomi Fujisawa; Tomoko Hirakata; Misa Iijima; Hiroyuki Kuwano
Journal:  World J Surg       Date:  2010-03       Impact factor: 3.352

2.  Analysis of molecular markers as predictive factors of lymph node involvement in breast carcinoma.

Authors:  Luciana Marques Paula; Luis Henrique Ferreira De Moraes; Abaeté Leite Do Canto; Laurita Dos Santos; Airton Abrahão Martin; Silvia Regina Rogatto; Renata De Azevedo Canevari
Journal:  Oncol Lett       Date:  2016-11-28       Impact factor: 2.967

3.  Predictive factors for non-sentinel lymph node involvement in breast cancer patients with a positive sentinel node: should we consider sentinel node-related factors?

Authors:  J L Fougo; M Afonso; F Senhorães Senra; T Dias; C Leal; C Araújo; M Dinis-Ribeiro
Journal:  Clin Transl Oncol       Date:  2009-03       Impact factor: 3.405

4.  Tumor characteristics influencing non-sentinel lymph node involvement in clinically node negative patients with breast cancer.

Authors:  Gunay Gurleyik; Fugen Aker; Ali Aktekin; Abdullah Saglam
Journal:  J Breast Cancer       Date:  2011-06-18       Impact factor: 3.588

5.  Thematic trends and knowledge structure map of sentinel lymph node biopsy for breast cancer: a bibliometric analysis from 2010 to 2019.

Authors:  Yujie Huo; Ting Fan; Si Chen; Qiannan Liu; Yue Fang; Fan Yao
Journal:  Transl Cancer Res       Date:  2022-09       Impact factor: 0.496

6.  Decreased Survival of Invasive Ductal Breast Cancer Patients With Two Macrometastatic Lymph Nodes Among Few Resected Ones: Should Current Sentinel-Lymph-Node Guidelines Be Revised?

Authors:  Felipe A C Luz; Rogério A Araújo; Marcelo J B Silva
Journal:  Front Oncol       Date:  2021-07-19       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.